Quantcast

Latest Boehringer Ingelheim Corporation Stories

2014-04-08 12:31:49

Three pivotal trials showed PRADAXA as non-inferior to warfarin in reduction of DVT and PE recurrence; fourth pivotal trial showed PRADAXA reduced risk of recurrence by 92 percent compared to placebo RIDGEFIELD, Conn., April 8, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa(®) (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in...

2014-04-07 08:31:34

Three pivotal trials showed PRADAXA as non-inferior to warfarin in reduction of DVT and PE recurrence; fourth pivotal trial showed PRADAXA reduced risk of recurrence by 92 percent compared to placebo RIDGEFIELD, Conn., April 7, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa(®) (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in...

2014-03-28 08:27:23

Cardiologists also believe their patients' top concern is the fear of experiencing a clot that leads to a stroke; real-world challenges may influence treatment decisions RIDGEFIELD, Conn., March 28, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced results from a new survey of cardiologists to understand their perceptions about anticoagulation, stroke risk reduction and goals for non-valvular atrial fibrillation (NVAF) therapy when prescribing warfarin or...

2014-03-24 08:28:21

Presentations to include research around antidote for dabigatran, a post-hoc analysis of data from the RE-LY® trial and data from the GLORIA(TM)-AF registry RIDGEFIELD, Conn., March 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that data from three company-sponsored PRADAXA studies will be presented at the American College of Cardiology 63(rd) Annual Scientific Session (ACC.14) in Washington, D.C., March 29 to 31, 2014. An oral presentation will...

2014-03-21 08:24:55

Positive opinion is based on data from one of the largest clinical registration programs in its class, involving more than 13,000 adults with type 2 diabetes RIDGEFIELD, Conn. and INDIANAPOLIS, March 21, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending approval of empagliflozin, an...

2014-03-06 08:30:17

Additional drug-drug interaction data for faldaprevir combined with commonly prescribed HIV medications also presented at CROI 2014 INGELHEIM, Germany and RIDGEFIELD, Conn., March 6, 2014 /PRNewswire/ -- Today Boehringer Ingelheim announced results from STARTVerso(®)4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg...

2014-03-05 12:26:22

Boehringer Ingelheim and Lilly are committed to working with the FDA RIDGEFIELD, Conn. and INDIANAPOLIS, March 5, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin. The complete response letter...

2014-03-01 12:20:30

For U.S. Media Only RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat(®) inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in San Diego. Tiotropium is being studied to determine its efficacy and safety in treating asthma patients and is not currently approved for this indication. The first results...

2014-01-30 12:28:26

Unique academic-industry partnership will include an IPF patient registry and biomarker bank RIDGEFIELD, Conn. and DURHAM, N.C., Jan. 30, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Duke Clinical Research Institute (DCRI) have formed a unique collaborative relationship to uncover insights into idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. As part of the partnership, Boehringer Ingelheim and Duke Clinical Research Institute will...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related